This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by SoRelle, R. Search for Related Content PubMed PubMed Citation Articles by SoRelle, R. Pubmed/NCBI databases Medline Plus Health Information Vascular Diseases

(Circulation. 1998;98:829-830.)
© 1998 American Heart Association, Inc.

Cardiovascular News

Vascular and Lipid Syndromes in Selected HIV-Infected Patients

Ruth SoRelle, Circulation Newswriter

Abizarre and unexpected set of vascular and lipid syndromes appears to afflict an as-yet-undetermined percentage of HIV-infected patients taking what is called highly active antiviral therapy. The syndromes, the subject of several presentations at the 12^th World AIDS Conference in Geneva, Switzerland, were among the most serious side effects of the therapy that has revolutionized AIDS treatment in industrialized nations.

HAART, as the treatment is more generally known, usually consists of 2 nucleoside reverse-transcriptase inhibitors and a protease inhibitor. Usually, 1 of the reverse-transcriptase inhibitors crosses the blood-brain barrier. These drugs interfere with the life cycle of the retrovirus at the point at which RNA is translated into the DNA that can be incorporated into the genetic blueprint of the cell. Protease inhibitors work later in the life cycle of the virus, preventing release of virions from the cellular machinery that has been subverted into a virus factory.

The syndrome consists of a lipodystrophy, with fat disappering from the limbs and distant areas of the body while concentrating in the trunk. There are often unusual fat deposits in the abdomen and a "buffalo hump" of fat in the upper shoulders. There were also some levels of serious insulin resistance and, in some cases, frank diabetes mellitus associated with the syndrome. Of even greater concern are high cholesterol and triglyceride levels—above where most physicians in the world would begin to treat, said David Cooper, MD, immediate past president of the International AIDS Society and a practicing physician at St Vincent's Hospital . . . [Full Text of this Article]

This article has been cited by other articles:

				H. Tran, S. Robinson, I. Mikhailenko, and D. K. Strickland Modulation of the LDL receptor and LRP levels by HIV protease inhibitors J. Lipid Res., October 1, 2003; 44(10): 1859 - 1869. [Abstract] [Full Text] [PDF]

				R. O. Cannon III Cardiovascular Benefit of Cholesterol-Lowering Therapy : Does Improved Endothelial Vasodilator Function Matter? Circulation, August 22, 2000; 102(8): 820 - 822. [Full Text] [PDF]

				R. P. Shannon, M. A. Simon, M. A. Mathier, Y.-J. Geng, S. Mankad, and A. A. Lackner Dilated Cardiomyopathy Associated With Simian AIDS in Nonhuman Primates Circulation, January 18, 2000; 101(2): 185 - 193. [Abstract] [Full Text] [PDF]